Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

site via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program, R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; risks associated with the Company's dependence on corporate collaborators for development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's urocortin 2, CRF1 receptor antagonist, and VMAT2 clinical candidates will not proceed to later stage clinical trials, and risk that the Company's research programs will not identify pre-clinical candidates for further development. The Company also faces risk that the Company may be unable to obtain FDA approval for indiplon commercialization in the near future or at all. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent p
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... PA (PRWEB) August 27, 2014 "It ... after going to the bathroom," said an inventor from ... effective way of performing this important hygienic task." He ... easy-to-use, patent-pending Fanny Wipe enables a user to wipe ... It ensures good hygiene and comfort, as well as ...
(Date:8/27/2014)... August 27, 2014 Discover Leadership Training ... and corporate transformation through their comprehensive leadership programs. As ... has unparalleled experience in the realm of outcome-focused and ... expertise in a new webinar series titled, “A Women’s ... The first of this two part webinar is titled, ...
(Date:8/27/2014)... CT (PRWEB) August 27, 2014 ... cyclists of all abilities to go the distance this ... Alex’s Million Mile – Run. Walk. Ride. initiative, hosted ... and increase awareness of childhood cancer. September represents ... year’s Alex’s Million Mile, Inspira Marketing Group has teamed ...
(Date:8/27/2014)... Crossing, PA (PRWEB) August 27, 2014 Time ... successfully launched its first-ever golf event! , With 80-degree ... for the Time To Play Golf (TTPGolf) Inaugural Outing. Around ... August 4th event, staged at the beautiful Heron Glen Golf ... with a bang and everyone seemed to be having a ...
(Date:8/27/2014)... PCOS (Polycystic Ovarian Syndrome) affects an estimated 1 ... a number of health disorders and medical conditions. However, ... within the medical community. Many women are suffering from ... body fat around the waist area (truncal obesity), but ... by PCOS. , Awareness is the first step to ...
Breaking Medicine News(10 mins):Health News:InventHelp Client's Device Helps a User Wipe Thoroughly After Going to the Bathroom (HLW-1300) 2Health News:Barb Moses, Vice President of Discover Leadership Training, Announces New Webinar Titled, “A Women’s Guide to Making Her Life Story a Bestseller” 2Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 2Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 3Health News:Recap: Time To Play Golf Inaugural Golf Outing 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 3Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 4Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 5
... Medical Innovations, Inc. (Amex: IMA ), a ... solutions, announced today that it will attend the upcoming ... 15, 2009 at the Westin St. Francis Hotel in ... Jon Russell, Vice President, Finance, will attend. Mr. ...
... Corporation (Nasdaq: BPUR ) announced today that ... stating that NASDAQ has again suspended enforcement of its ... listing, thereby extending the Company,s time in which to ... to resume on Monday, April 20, 2009. The Company ...
... Executive with Proven Ability to Develop Companies into ... Growth OpportunitiesFORT LAUDERDALE, Fla., Dec. 30 eDiets.com, ... provider of convenient at-home diet, fitness and healthy ... the company,s new President and CEO, effective immediately. ...
... didn,t halt women,s risk of developing disease , , TUESDAY, ... the supposed cancer-fighting powers of vitamins C and E, ... don,t prevent the disease in women. , And another ... new study found. , , "Simply taking antioxidant supplements ...
... had cancer as well as idiopathic pulmonary fibrosis, study finds ... in a gene previously found to help protect the lungs ... some inherited cases of a lethal lung disease affecting older ... the SFTPA2 gene have been found in families ...
... of adults and 19 percent of children taking chemotherapy drugs ... dose or experienced other mistakes involving their medications, according to ... professor of pediatrics at the University of Massachusetts Medical School, ... Journal of Clinical Oncology . , "As cancer care ...
Cached Medicine News:Health News:Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009 2Health News:Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 3Health News:Vitamins Fail to Prevent Cancer: Study 2Health News:Vitamins Fail to Prevent Cancer: Study 3Health News:Gene Mutation Tied to Inherited Fatal Lung Disease 2Health News:Errors involving medications common in outpatient cancer treatment 2
(Date:8/26/2014)... Research and Markets  has announced the addition of ... to their offering. Cytomegalovirus retinitis is ... organism of this disease is cytomegalovirus, a herpes virus ... disease can lead to permanent blindness if left untreated. ... other eye if neglected. The virus is very commonly ...
(Date:8/26/2014)... 26, 2014 Research and Markets ... "Global Veterinary Diagnostics Market 2014-2018" report to ... various tests, which are used to detect diseases ... biomedical researchers are mainly availing these diagnostic services. ... Acid testing), immunodiagnostics, clinical chemistry, and hematology. These ...
(Date:8/26/2014)... , Aug. 26, 2014  Ethicon* is introducing ... address the unique challenges of bariatric procedures such as ... was made today at the 19th World Congress of ... Disorders (IFSO 2014), where Ethicon is featuring the new ... 45cm ENSEAL ® G2 Articulating Tissue Sealer alongside ...
Breaking Medicine Technology:Global Cytomegalovirus Retinitis Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, Hospira and Shire 2Global Cytomegalovirus Retinitis Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, Hospira and Shire 3Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 2Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 3Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 2Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 3Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 4Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 5Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 6
... 6, 2011 Reportlinker.com announces that ... available in its catalogue: ... Emerging Opportunities ... of small-scale electronics and sophisticated biocompatible ...
... Oct. 6, 2011 Reportlinker.com announces ... is available in its catalogue: ... and Market Forecasts to 2016 - ... Uptake of Novel Drugs in the ...
Cached Medicine Technology:Continuous Glucose Monitors: Evolving Technology, Emerging Opportunities 2Continuous Glucose Monitors: Evolving Technology, Emerging Opportunities 3Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 2Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 3Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 4Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 5Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 6Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 7Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 8Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 9Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 10Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 11Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 12Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 13
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: